Altium Capital Management LLC Acquires New Shares in ImmunityBio, Inc. (NASDAQ:IBRX)

Altium Capital Management LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,060,000 shares of the company's stock, valued at approximately $2,714,000. Altium Capital Management LLC owned about 0.15% of ImmunityBio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Stephens Inc. AR acquired a new position in ImmunityBio in the fourth quarter valued at $26,000. Cibc World Markets Corp acquired a new position in shares of ImmunityBio in the 4th quarter valued at about $35,000. Virtu Financial LLC acquired a new position in shares of ImmunityBio in the 3rd quarter valued at about $51,000. Maia Wealth LLC acquired a new stake in ImmunityBio during the 4th quarter worth approximately $37,000. Finally, Schechter Investment Advisors LLC purchased a new position in ImmunityBio in the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 8.58% of the company's stock.

ImmunityBio Price Performance

Shares of IBRX traded up $0.07 during trading hours on Wednesday, reaching $2.76. 3,522,435 shares of the company's stock traded hands, compared to its average volume of 5,806,178. ImmunityBio, Inc. has a twelve month low of $2.28 and a twelve month high of $10.53. The business's fifty day simple moving average is $2.92 and its two-hundred day simple moving average is $3.49. The firm has a market capitalization of $2.36 billion, a price-to-earnings ratio of -3.00 and a beta of 0.51.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.74 million. On average, equities research analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on IBRX. BTIG Research assumed coverage on shares of ImmunityBio in a research report on Friday, January 10th. They issued a "buy" rating and a $6.00 price objective for the company. D. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a research report on Wednesday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a research report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, ImmunityBio currently has an average rating of "Buy" and a consensus price target of $12.19.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.